The choice of model organism is central to the study’s design. The team used Drosophila melanogaster flies genetically modified to express human amyloid-beta 42, the sticky peptide that aggregates into the plaques characteristic of Alzheimer’s disease. Although flies are distant from humans on the evolutionary tree, they share a remarkable proportion of their genes with people, and many of the molecular pathways implicated in neurodegeneration, including oxidative stress responses, cholinergic signalling, and tau phosphorylation cascades, are conserved. Fruit flies also live for only weeks, which means researchers can observe the full course of a neurodegenerative process and test interventions across the lifespan in a matter of days, something impossible in rodent or human studies. In this experiment, the Alzheimer-model flies were treated with the Caralluma extract for fourteen days before being assessed.

The behavioural results were the most visible evidence of benefit. Flies carrying the human amyloid-beta 42 gene typically show progressive deterioration in climbing ability, a standard measure of locomotor function in fly neurodegeneration research, as well as impaired grooming and deficits in learning assays. Treated flies performed significantly better across these measures and lived longer than their untreated counterparts. The researchers used an aversive phototaxis suppression assay to probe learning and memory, a test that measures a fly’s ability to suppress its natural attraction to light when that light is paired with an unpleasant stimulus. Improved performance in this assay suggests that the extract protected cognitive function, not merely motor capacity, although the authors are careful to frame these as preliminary findings in an invertebrate system.

Beneath the behavioural improvements, the biochemical data pointed to a familiar theme in neurodegeneration research: oxidative stress. The brains of Alzheimer-model flies suffer from an excess of reactive oxygen species that damage lipids, proteins, and DNA. The team measured malondialdehyde, a breakdown product of lipid peroxidation that serves as a marker of oxidative damage, and found it reduced in treated flies. At the same time, levels of the antioxidants glutathione and superoxide dismutase, two of the cell’s primary defences against oxidative injury, were increased. This shift in the balance between oxidative damage and antioxidant capacity is consistent with a neuroprotective effect and aligns with the known chemistry of many plant-derived polyphenols, which can act as antioxidants directly and can also induce the cell’s own antioxidant defence systems.

Perhaps the most pharmacologically interesting finding concerned acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine. Cholinergic neurons in the brain are among the earliest casualties of Alzheimer’s disease, and the loss of acetylcholine contributes substantially to the memory impairment that defines the condition. Four of the currently approved Alzheimer’s drugs, including donepezil and galantamine, work by inhibiting acetylcholinesterase to keep acetylcholine available for longer in the synaptic cleft. In the treated flies, acetylcholinesterase levels were significantly reduced, suggesting that the extract may reproduce, at least partially, the mechanism of existing symptomatic therapies through a natural product mixture.

The molecular layer of the study focused on tau, the microtubule-associated protein whose pathological tangles inside neurons form the second hallmark lesion of Alzheimer’s disease alongside amyloid plaques. Quantitative analysis showed that the fly equivalent of the tau gene, dTau, was downregulated in extract-treated flies compared with untreated Alzheimer-model flies. Because tau pathology correlates more closely with cognitive decline than amyloid burden in human disease, any intervention that reduces tau expression or the signalling that drives tau phosphorylation attracts considerable attention. The researchers propose that the extract may be acting upstream of tau through pathways that connect amyloid toxicity to tau dysfunction.

To explore those upstream connections, the team turned to molecular docking, a computational technique that predicts how well small molecules fit into the binding pockets of target proteins. They focused on two enzymes with central roles in Alzheimer’s biology: glycogen synthase kinase-3, known as GSK3, and beta-secretase 1, known as BACE1. GSK3 is the major kinase that phosphorylates tau in the brain, promoting its aggregation into tangles, and it also participates in inflammatory and apoptotic signalling. BACE1 is the enzyme that performs the first cut in the production of amyloid-beta from its parent protein, making it a prime drug target for reducing amyloid generation. Docking simulations suggested that several phytochemicals present in the extract interact favourably with both enzymes, with catechin, a flavonoid found in many plants, showing the most promising predicted binding profiles against GSK3 and BACE1 alike.

The authors are explicit that docking is a hypothesis-generating tool rather than proof of mechanism. Predicted binding energies do not confirm that catechin or any other constituent of the extract actually inhibits GSK3 or BACE1 inside a living organism, and the extract is a complex mixture whose active components and their concentrations remain to be fully characterised. The study also did not directly measure amyloid-beta deposition or tau phosphorylation in the fly brains, so the link between the observed gene expression changes and the actual pathological lesions of Alzheimer’s disease remains to be established. Direct target validation, the authors note, together with assessment of amyloid and tau pathology and studies in mammalian models, will be required before any therapeutic relevance can be claimed.

Even with those caveats, the study fills a genuine gap. Caralluma dalzielii has a long history of traditional use for neurological complaints in the region where it grows across the Sahel and West Africa, yet it had never previously been evaluated in an experimental model of Alzheimer’s disease. Its close relative Caralluma fimbriata has been studied mainly for appetite suppression, and the genus as a whole remains underexplored relative to its chemical richness. Plants in this group produce an array of pregnane glycosides, flavonoids, and other secondary metabolites, and the new findings suggest that some of these compounds may act on multiple nodes of the Alzheimer’s disease network simultaneously, a polypharmacology that single-target drugs often lack.

The research also demonstrates the continuing value of the humble fruit fly in early-stage drug discovery. A complete behavioural, biochemical, and molecular evaluation of a natural product extract was accomplished in a model system that is inexpensive, rapid, and free of the ethical and logistical constraints of vertebrate studies, supported by funding from Nigeria’s TETFund institutional research programme. For a disease that affects tens of millions of people worldwide and for which approved therapies offer only modest symptomatic benefit, the pipeline of candidate compounds needs every accessible entry point. The Nigerian team’s results do not amount to a treatment, and no one should interpret them as a recommendation to seek out the plant itself. What they provide is a rigorous preliminary signal, generated through a transparent and reproducible workflow, that Caralluma dalzielii deserves a place in the queue of natural products being screened for Alzheimer’s drug discovery. If catechin and its neighbours in the extract can be isolated, validated against GSK3 and BACE1 in vitro, and tested in mammalian models of the disease, this Sahelian succulent may yet contribute more to modern medicine than its traditional reputation alone ever suggested.

Subject of Research: Neuroprotective effects of Caralluma dalzielii extract in a transgenic Drosophila model of Alzheimer's disease

Article Title: Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model

Article References: Ugwah-Oguejiofor, C. J., Hassan, E., Yakubu, D., Ahmed, A. H., Almustapha, Z., & Imam, M. U. (2026). Targeting Alzheimer’s disease pathways with Caralluma dalzielii: behavioural, biochemical, and molecular evidence from a transgenic Drosophila melanogaster model. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05637-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05637-3

Keywords: Caralluma dalzielii, Alzheimer's disease, Drosophila melanogaster, amyloid-beta 42, tau, GSK3, BACE1, acetylcholinesterase, oxidative stress, catechin, phytochemicals, molecular docking

Coumarin, formally known as 2H-chromen-2-one, is a scaffold that nature and medicinal chemists have exploited for decades. It appears in natural products such as esculetin, decursinol, and scopoletin, each carrying a portfolio of pharmacological effects ranging from antioxidant and anti-inflammatory activity to documented acetylcholinesterase inhibition. Because the coumarin core offers six positions for chemical substitution, it provides an unusually flexible platform for building drug candidates. Previous biscoumarin derivatives, in which two coumarin units are linked through a central carbon, have already shown antiviral, urease-inhibitory, antiglycation, and even potential HIV-1 integrase blocking properties, making the scaffold a proven starting point for new therapeutic exploration.

The research team, led by Mohamed H. Helal and Ahmed M. El-Agrody with collaborators across Egypt and the United Arab Emirates, set out to make 4H-pyran-coumarin hybrids through a well-established three-component reaction between a 4-hydroxycoumarin, aromatic aldehydes, and malononitrile. Instead, the reaction took an unexpected turn. When 6-ethyl-4-hydroxy-2H-chromen-2-one was refluxed with a series of para-halogenated benzaldehydes in ethanol with piperidine as the base, the anticipated pyran-coumarin products never materialized. Rather than forming the hypothetical intermediate that would have reacted with malononitrile, the coumarin attacked the aldehyde twice, delivering a family of bis-coumarins in which a central methine carbon bridges two coumarin units, each bearing a pendant 4-halophenyl group with fluorine, chlorine, bromine, or iodine at the para position.

The mechanistic story behind this surprise is a textbook cascade of organic transformations. Piperidine first abstracts the acidic proton from the keto tautomer of the coumarin, generating a resonance-stabilized enolate. That nucleophile attacks the aldehyde carbonyl, and the resulting hydroxyl intermediate dehydrates to an alpha,beta-unsaturated species. A second coumarin enolate then performs a 1,4-Michael addition onto this activated double bond, forging a new carbon-carbon bond, and a final proton shift delivers the bis-coumarin product while regenerating the base catalyst. The sequence elegantly explains why the two-component condensation outcompeted the intended three-component pathway.

Structural proof came from an arsenal of spectroscopic techniques. Infrared spectra revealed hydroxyl stretches near 3275 per centimeter and lactone carbonyl absorptions around 1772 per centimeter, while proton and carbon NMR confirmed the characteristic methine, methylene, and methyl signals of the ethyl substituents. Advanced two-dimensional experiments, including COSY, HSQC, HMBC, and DEPT spectra, allowed the team to assign all sixteen carbon resonances unambiguously. The decisive evidence, however, arrived from single-crystal X-ray diffraction. All four derivatives crystallized in the monoclinic space group P 21/n, and the structures revealed a striking butterfly-like arrangement in which the two coumarin moieties adopt an anti-conformation locked by strong intramolecular hydrogen bonds between the 4-hydroxyl groups and the adjacent lactone carbonyl oxygens, with oxygen-oxygen distances of roughly 2.6 to 2.7 angstroms.

The crystallographic data also exposed a systematic trend across the halogen series. As the halogen grows from fluorine to iodine, the unit cell volume expands by nearly four percent, calculated densities climb from 1.311 to 1.543 grams per cubic centimeter thanks to the heavy atom effect, and the carbon-halogen bond lengths stretch from 1.368 to 2.096 angstroms, exactly as atomic radii predict. Hirshfeld surface analysis quantified the intermolecular contacts, showing that the fluorinated compound presents the most pronounced close-contact hot spots while the iodinated derivative offers the most balanced surface. Halogen-halogen contacts in the chloro, bromo, and iodo structures all fall short of the sum of van der Waals radii, confirming attractive type II halogen bonding that helps stitch the crystals together.

With the structures secured, the team turned to biology, and the results are what make this study genuinely exciting. Against acetylcholinesterase, measured with a modified Ellman assay, the chlorinated derivative emerged as the star performer with an IC50 of 1.484 micromolar, followed by the fluoro analogue at 2.535 micromolar. The bulkier bromine and iodine versions lagged behind at 3.757 and 5.240 micromolar respectively, all compared against the FDA-approved drug donepezil at 0.711 micromolar. The pattern reversed for monoamine oxidase-B, where the fluorinated compound took the lead with an IC50 of 1.006 micromolar, essentially matching the reference inhibitor tranylcypromine at 0.95 micromolar, while the chloro compound followed at 1.783 micromolar.

This divergence is the crux of the structure-activity relationship. Acetylcholinesterase possesses a narrow, twenty-angstrom gorge lined with aromatic residues, and docking simulations against the human enzyme structure 4EY7 showed that the chlorinated derivative spans the entire gorge, forming a halogen bond with the backbone of Ser293 and pi-pi stacking with Tyr341 and Tyr72. Chlorine, with its moderate van der Waals radius of about 1.75 angstroms and a significant sigma-hole, hits a Goldilocks balance of hydrophobic complementarity and directional bonding. Bromine and iodine, by contrast, trigger steric clashes with mid-gorge residues such as Phe295 and Met436, twisting the scaffold out of its optimal orientation. Monoamine oxidase-B presents a different challenge: a hydrophobic substrate cavity guarded by the dynamic Ile199 gate near the FAD cofactor. Here, fluorine’s small size lets the molecule slip through the gate and approach the flavin, while larger halogens are excluded to the entrance cavity, a picture that docking against the safinamide complex 4A79 vividly confirmed. Binding energies from the simulations correlated strongly with experimental potency, yielding R-squared values of 0.94 for acetylcholinesterase and 0.86 for monoamine oxidase-B.

Why does dual inhibition matter? The cholinergic hypothesis holds that Alzheimer’s symptoms stem from depleted acetylcholine, and every FDA-approved Alzheimer’s drug except memantine works by blocking acetylcholinesterase. Meanwhile, monoamine oxidase-B activity rises with age and in Alzheimer’s patients, generating hydrogen peroxide and free radicals that damage neurons and contribute to amyloid plaque formation. A single molecule that hits both targets could, in principle, address multiple facets of the disease simultaneously, a strategy increasingly favored for multifactorial conditions. The rigid, pre-organized anti-conformation enforced by the intramolecular hydrogen bonds may also enhance metabolic stability and membrane permeability, though those properties remain to be tested directly.

The road from micromolar enzyme inhibition to a medicine is long, and the authors are candid about the next steps: optimizing pharmacokinetics, testing in vivo efficacy in animal models, and designing hybrid derivatives that cross the blood-brain barrier more effectively. Future analogues might swap the 6-ethyl group for other small chains to fine-tune lipophilicity, or combine fluoro and chloro features to balance the distinct steric demands of the two enzymes. Still, the study delivers something rarer than a single hit compound. It provides a validated molecular template, a crystallographically grounded understanding of how halogen identity tunes potency at two different neurological targets, and a vivid demonstration that even a failed reaction can open an unexpected door, provided someone looks closely enough at the crystals that fall out of the flask.

Subject of Research: Synthesis and biological evaluation of halogenated bis(6-ethyl-4-hydroxy-2H-chromen-2-one) derivatives as dual acetylcholinesterase and monoamine oxidase-B inhibitors

Article Title: Synthesis of novel bis(6-ethyl-4-hydroxy-2 H -chromen-2-one) derivatives as potential acetylcholinesterase and monoamine oxidase inhibitors

Article References: Helal, M. H., Alrashdi, S., Alshareef, H. F., Moussa, Z., Elgammal, W. E., Halawa, A. H., Elhenawy, A. A., & El-Agrody, A. M. (2026). Synthesis of novel bis(6-ethyl-4-hydroxy-2H-chromen-2-one) derivatives as potential acetylcholinesterase and monoamine oxidase inhibitors. Results in Chemistry, 31, Article 103951. https://doi.org/10.1016/j.rechem.2026.103951

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103951

Keywords: coumarin, bis-coumarin, acetylcholinesterase, monoamine oxidase-B, Alzheimer's disease, enzyme inhibitors, X-ray crystallography, molecular docking, halogen bonding, structure-activity relationship, drug discovery, organic synthesis

The urgency behind the work stems from a familiar and worsening problem. Vector-borne diseases such as dengue, chikungunya, filariasis and West Nile fever continue to burden public health systems worldwide, while mosquito populations have grown steadily resistant to the synthetic chemicals deployed against them. Resistance typically arises through enhanced detoxification and reduced sensitivity of the target protein, eroding the effectiveness of organophosphates and carbamates that act on the cholinergic nervous system. Plant-derived phytochemicals, which are biodegradable, less persistent in the environment and often less toxic to non-target organisms, have attracted growing interest as alternatives. Previous studies have shown larvicidal effects of plant extracts ranging from Cassia fistula flowers to Calotropis procera leaves, but crude extracts blur the identity of the active molecule. What distinguishes the new study is its focus on a single, purified, structurally characterized compound.

Andrograpanin itself has an interesting pedigree. It is a deoxygenated analog of andrographolide, the principal bitter diterpenoid of A. paniculata, a plant widely known as the ‘king of bitters.’ For the study, fresh leaves were collected from Palayamkottai in Tamil Nadu, India, authenticated by the Siddha Central Research Institute in Chennai, and processed from 1.5 kilograms of shade-dried material. Successive Soxhlet extraction with hexane, chloroform and methanol yielded a methanol extract that showed the highest bioactivity. Silica gel column chromatography, eluted with a chloroform-ethyl acetate mixture, then delivered andrograpanin as a colorless crystalline solid melting at 103 to 104 degrees Celsius. Infrared, proton and carbon NMR, and GC-MS analyses confirmed a labdane diterpenoid with the formula C20H30O3 and a molecular mass of 318, featuring the gamma-lactone carbonyl and exomethylene groups characteristic of the compound.

Before any docking could begin, the team needed biological evidence that the molecule actually kills mosquitoes. Using standardized World Health Organization guidelines with five replicates per assay, and probit analysis to derive lethal concentrations, the researchers tested ovicidal, larvicidal and pupicidal activity against both species. The results were striking for a natural product. At just 2 parts per million, andrograpanin killed 72 percent of Ae. aegypti eggs and 78 percent of Cx. quinquefasciatus eggs. Larval LC50 values came in at 1.18 ppm for Ae. aegypti and 1.10 ppm for Cx. quinquefasciatus, with LC90 values of 2.74 and 2.55 ppm respectively. Pupae proved slightly hardier, with LC50 values of 1.33 and 1.25 ppm. These potencies, achieved by a single purified phytochemical at parts-per-million concentrations, provided the biological anchor for the computational question that followed: what molecular target might explain this activity?

The obvious candidate was acetylcholinesterase, the enzyme that sits at the heart of insect neurochemistry. Acetylcholinesterase hydrolyzes the neurotransmitter acetylcholine in the synaptic cleft, terminating each nerve impulse and resetting the synapse for the next signal. Block the enzyme, and acetylcholine accumulates, firing postsynaptic receptors continuously until the insect convulses, becomes paralyzed and dies. This is precisely the mechanism exploited by organophosphate and carbamate insecticides, which makes AChE1 a validated and well-characterized target. If andrograpanin could be shown to occupy the same binding pocket, it would generate a plausible mechanistic explanation for the observed mosquitocidal activity.

Because no experimental crystal structures existed for AChE1 from either mosquito species, the team built homology models using SWISS-MODEL, retrieving protein sequences from UniProtKB and selecting the crystal structure of an insecticide-resistant acetylcholinesterase mutant from Anopheles gambiae (PDB ID 6ARY) as the template. The resulting models captured the conserved catalytic domain, including the deep substrate-binding gorge where ligand recognition occurs. Validation was rigorous: Ramachandran plot analysis via PROCHECK placed 94.8 percent of Ae. aegypti residues in the most favored region with no disallowed positions, while the Cx. quinquefasciatus model showed 88.7 percent in the highly preferred region and also no disallowed residues. QMEAN scoring assessed global model quality, and CASTp analysis identified the principal binding pocket and the active-site residues involved in the enzyme’s hydrolase function, defining the docking arena.

The docking itself was performed with AutoDock Tools using a Lamarckian Genetic Algorithm, with each experiment comprising ten runs, 150 individuals in the population and 500,000 energy evaluations on a grid of 60 by 60 by 60 points at 0.375 angstrom spacing. The receptor was held rigid while the ligands were flexible. Andrograpanin emerged with a predicted binding energy of minus 6.36 kcal/mol against Ae. aegypti AChE1 and minus 6.45 kcal/mol against Cx. quinquefasciatus AChE1, with a ligand efficiency of 0.28 in both cases. In the Ae. aegypti model, the compound formed two conventional hydrogen bonds, one with the polar residue HIS47 at 3.02 angstroms and one involving the backbone of ILE91 at 2.11 angstroms, along with hydrophobic contact with TYR43 and carbon-hydrogen bonds with TYR45. In Cx. quinquefasciatus, it hydrogen-bonded with ASN65 and the GLY96 backbone, and made carbon-hydrogen contacts with SER44 and PRO64, all clustered around the catalytic gorge.

Temephos, docked under identical conditions as the reference standard, fared measurably worse. Against Ae. aegypti AChE1 it scored minus 4.36 kcal/mol with a ligand efficiency of 0.16, and against Cx. quinquefasciatus AChE1 it scored minus 4.06 kcal/mol with an efficiency of 0.20. Converted to inhibition constants through the thermodynamic relationship ΔG = RT ln(Ki) at 298.15 kelvin, the numbers diverge dramatically: andrograpanin’s Ki values ranged from 18.69 to 21.76 micromolar, while temephos ranged from 636.46 to 1056.07 micromolar, roughly a fifty-fold difference in predicted binding favorability. The comparison gains context from earlier docking studies of plant compounds against mosquito AChE1, which have reported scores from about minus 5.2 to minus 8.5 kcal/mol for molecules such as β-isocostic acid, longifolene and α-solanine. Andrograpanin’s values sit squarely within that range, though the authors caution that cross-study comparisons are complicated by differences in receptor structures, algorithms and scoring functions.

The novelty of the work lies in its integration. Rather than docking a hypothetical ligand or a crude extract, the team combined a purified, spectroscopically confirmed compound with experimentally validated ovicidal, larvicidal and pupicidal bioassays and a head-to-head computational comparison with a commercial insecticide under identical docking conditions. That convergence of biological and computational evidence strengthens the case for andrograpanin as a lead molecule for sustainable mosquito control, and the interaction profile, with hydrogen bonds and hydrophobic contacts surrounding the substrate-binding pocket, suggests the compound could interfere with substrate access or stabilization of the enzyme-substrate complex.

Yet the authors are unusually candid about the limits of their evidence. Molecular docking predicts a static binding pose and cannot fully capture protein flexibility, solvent effects or conformational dynamics, and the study lacks molecular dynamics simulations that would test whether the docked complexes remain stable over time. The absence of archived SWISS-MODEL project files also prevented reporting of detailed template alignment statistics. Most importantly, no direct acetylcholinesterase inhibition assay has yet been performed, so the proposed mechanism remains a computational hypothesis rather than demonstrated biochemistry. The docking energies, while more favorable than temephos’s, represent only moderate predicted affinities and should not be read as proof of potent enzyme inhibition. The path forward, the researchers argue, runs through enzyme inhibition assays, molecular dynamics simulations with MM/PBSA or MM/GBSA binding free-energy calculations, toxicity testing against non-target organisms and field trials. If those steps confirm what the docking suggests, a bitter leaf from southern India may yet yield a weapon against two of humanity’s most persistent disease vectors.

Subject of Research: Molecular docking of the plant diterpenoid andrograpanin with acetylcholinesterase 1 from Aedes aegypti and Culex quinquefasciatus mosquitoes

Article Title: Molecular docking analysis of andrograpanin interactions with acetylcholinesterase from Aedes aegypti and Culex quinquefasciatus

Article References: Vilvest, J., Milton, M. C. J., Yagoo, A., & Stalin, A. (2026). Molecular docking analysis of andrograpanin interactions with acetylcholinesterase from Aedes aegypti and Culex quinquefasciatus. Discover Chemistry, 3(1), Article 477. https://doi.org/10.1007/s44371-026-00933-w

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00933-w

Keywords: andrograpanin, acetylcholinesterase, molecular docking, Aedes aegypti, Culex quinquefasciatus, mosquito control, Andrographis paniculata, temephos, botanical insecticides, homology modeling, insecticide resistance, vector-borne disease

The economics alone make a compelling case for the computational turn. According to figures cited in the review, bringing a single new active ingredient to market has historically required the synthesis and evaluation of roughly 159,000 compounds, at a cost approaching 286 million US dollars and an average development timeline of about 11.5 years from first synthesis to commercial launch. Meanwhile, the environmental bill keeps mounting: more than 99 percent of applied pesticides never reach their intended target, dispersing instead into air, soil, and water, where they disrupt pollinators and other beneficial organisms. Human health concerns add urgency, with epidemiological studies linking pesticide exposure to elevated risks of neurodegenerative diseases such as Parkinson’s and Alzheimer’s, particularly among agricultural workers. Against this backdrop, the review’s authors, led by Mohamed El Ammari, position computational methods as essential instruments for finding compounds that are simultaneously effective, selective, and environmentally benign.

At the heart of the review is molecular docking, a structure-based technique that predicts how a small molecule—a ligand—binds to a macromolecular target such as a protein. The method rests on the physics of molecular recognition: hydrogen bonds, ionic interactions, hydrophobic effects, and van der Waals forces jointly determine the stability of a ligand–protein complex. A docking workflow typically involves preparing three-dimensional structures of both receptor and ligand, modeling their interactions, and scoring the resulting complexes by estimated binding energy to identify the most favorable binding conformation. Docking can be rigid, semi-flexible, or flexible, each mode trading computational cost against accuracy. In insecticide research, the technique supports virtual screening of chemical libraries, investigation of molecular targets, analysis of resistance-associated mutations, and even reverse docking, in which researchers start from a compound and search for the proteins it might bind—an approach that can flag potential off-target interactions with toxicological consequences.

The review is careful to emphasize that docking is not a crystal ball. Scoring functions remain imperfect, receptor flexibility is hard to capture, and ligand protonation, solvation effects, and protein preparation all introduce uncertainty. A favorable docking score, the authors stress, should be read as a comparative computational indicator, not as a direct measurement of binding affinity or biological activity. The most convincing studies therefore embed docking within multi-layered validation schemes that include enzyme inhibition assays, organism-level toxicity and behavioral bioassays, and, where possible, molecular dynamics simulations and free-energy calculations. When those elements converge, candidate prioritization becomes markedly more reliable, separating genuinely actionable leads from what the authors call pose-driven artifacts.

The case studies assembled in the review span an impressive range of pests, compounds, and targets, and many of them pair computational predictions with hard experimental numbers. In one study, homology modeling and virtual screening identified sulfonamide leads targeting the vacuolar-type ATPase of the oriental armyworm Mythimna separata; synthesis of 71 derivatives yielded seven with strong insecticidal activity. Another team used structure-based virtual screening to find azo-aminopyrimidine inhibitors of the chitinase OfChi-h, with two compounds outperforming the commercial insecticide hexaflumuron against the diamondback moth and the European corn borer under the reported assay conditions. High-throughput screening against the glutamate-cysteine ligase catalytic subunit of the red flour beetle Tribolium castaneum produced a hit with an IC50 of 19.70 micromolar that caused 63.8 percent larval mortality in follow-up bioassays. These are not abstract predictions; they are molecules that kill insects in the laboratory.

Botanical chemistry features prominently throughout the synthesis, reflecting intense interest in plant-derived insecticides. Essential oils from garlic and mustard, rich in diallyl disulfide and allyl isothiocyanate, showed the strongest fumigant toxicity among tested oils against stored-grain pests, with docking revealing high-affinity binding of allyl isothiocyanate to arylalkylamine N-acetyltransferase and of 2-pentenenitrile to juvenile hormone esterase. Carvacrol, a monoterpene from oregano and thyme, displayed multi-target activity in Tribolium castaneum, binding acetylcholinesterase, glutathione S-transferase, and cytochrome P450 with predicted affinities exceeding those of chlorpyrifos, while biochemical assays confirmed enzyme inhibition and oxidative stress. Cymbopogon essential oils, clove oil, and Artemisia extracts all received similar docking-supported evaluations, with median lethal doses reported alongside binding energies. The review also includes instructive failures: garden-waste compost tea showed weak insecticidal activity against aphids despite docking analyses, a reminder that matrix effects and volatile loss can decouple computational predictions from field-like performance.

Endocrine targets emerge as one of the most productive arenas for structure-guided design. Docking of 25 non-azadirachtin neem limonoids to the ecdysone receptor ligand-binding domain of the cotton bollworm Helicoverpa armigera identified six high-affinity candidates, including nimbolide and azadirone, that outperformed the commercial insect growth regulator tebufenozide, with binding energies between −10.54 and −12.22 kilocalories per mole. Equally important, the same modeling logic explains selectivity: homology models of the ecdysone receptor in lacewings, beneficial insects used in biological control, revealed a restricted binding pocket that sterically clashes with tebufenozide, consistent with bioassays showing the compound is harmless to these predators. On the juvenile hormone axis, virtual screening identified phytochemical inhibitors of farnesyl diphosphate synthase, and geranylgeraniol was validated as an inhibitor of farnesol dehydrogenase, causing developmental defects and roughly 63 percent mortality in bollworm larvae. Together, these workflows illustrate a coherent path from target identification through modeling to experimental confirmation.

Resistance biology is another domain where in silico tools deliver explanatory and predictive value. In the silverleaf whitefly Bemisia tabaci, analysis of acetylcholinesterase gene polymorphisms across 30 field populations in Egypt and Pakistan, combined with homology modeling and docking, revealed mutations that alter the peripheral anionic site architecture and could reduce sensitivity to organophosphates and carbamates. In mosquitoes, RNA interference knockdown of eight overexpressed cytochrome P450 genes significantly reduced permethrin resistance, while docking rationalized the substrate scope underlying detoxification. Synergism studies point toward practical stewardship strategies: benzyl alcohol potentiated deltamethrin in houseflies by roughly an order of magnitude, with docking showing the two molecules binding complementary sites on acetylcholinesterase and the voltage-gated sodium channel, and quercetin synergized organophosphates in flour beetles through predicted inhibition of detoxifying P450 enzymes. Such insights directly inform insecticide rotation, mixture design, and the deployment of synergists.

Safety assessment is woven into the computational pipeline through ADMET prediction—modeling absorption, distribution, metabolism, excretion, and toxicity—which the review identifies as critical given that pharmacokinetic and toxicological failures account for up to 40 percent of drug development failures. Free web servers such as SwissADME and pkCSM, alongside commercial platforms, allow researchers to profile lipophilicity, solubility, and drug-likeness before any synthesis begins, reducing animal testing and avoiding late-stage failures from unforeseen toxicity. The honeybee voltage-gated sodium channel AmNaV1 offers a concrete example of selectivity-by-design: functional expression, electrophysiology, and docking of pyrethroids established a joint in vitro and in silico toolkit for appraising pollinator risk from current and next-generation pesticides. The authors advocate extending such counter-screening to aquatic and soil organisms as lead optimization proceeds.

The review closes with candid reflection on the field’s blind spots. A marked taxonomic bias concentrates computational innovation on a handful of model pests—lepidopterans, beetles, hemipterans, and dipterans—whose genomes, protein structures, and rearing systems are well characterized, while many regionally important pests, mites, and beneficial insects remain underrepresented, leaving homology models less reliable and docking outputs more uncertain. The authors call for standardized, transparent computational protocols, early counter-screens on pollinators, deconvolution of botanical mixtures into component target networks, and tight iterative cycles in which computational hypotheses are immediately stress-tested by discriminating experiments. Coupled with emerging machine-learning approaches, graph neural networks, and rapid free-energy methods, they argue, these practices could finally deliver mechanism-based, species-selective insecticides—provided that computation never drifts far from the laboratory bench that must ultimately validate it.

Subject of Research: Application of molecular docking and in silico computational methods to insecticide discovery and toxicological assessment

Article Title: Molecular docking and in silico approaches for insecticide discovery and toxicological assessment: A review

Article References: El Ammari, M., Bouzakraoui, S., Mrabti, I., Fahad, K., Boukita, H., Idrissi, A., Brhadda, N., & Ziri, R. (2026). Molecular docking and in silico approaches for insecticide discovery and toxicological assessment: A review. Results in Chemistry, 31, Article 103920. https://doi.org/10.1016/j.rechem.2026.103920

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103920

Keywords: molecular docking, insecticide discovery, virtual screening, in silico, pesticide resistance, biopesticides, ADMET prediction, acetylcholinesterase, ecdysone receptor, essential oils, integrated pest management, QSAR

The study was led by Peter M. Chilipweli and Elias C. Nyanza of the Catholic University of Health and Allied Sciences in Mwanza, together with Aiwerasia Vera Ngowi of Muhimbili University of Health and Allied Sciences and Karim Manji, also of Muhimbili. Their team recruited 337 mother–child pairs from reproductive and child health clinics across four districts in the Iringa and Njombe regions. Of these, 220 came from districts classified in advance as pesticide-exposed — Kilolo and Makambako, both centers of intensive horticulture — while 117 came from comparison districts, Njombe Town and Iringa Municipal, where agricultural chemical use is expected to be lower.

The central measurement was erythrocyte acetylcholinesterase activity, assessed during the first trimester of pregnancy. Acetylcholinesterase is the enzyme that breaks down acetylcholine, the neurotransmitter released at nerve synapses, and organophosphate insecticides work precisely by inhibiting this enzyme, causing overstimulation of nerve pathways. Because red blood cell acetylcholinesterase mirrors the enzyme found at nerve endings, its activity in maternal blood serves as a widely used proxy for the body’s internal dose of organophosphate exposure. The researchers classified each mother as having either low inhibition or high or moderate inhibition of the enzyme. Overall, 38.3 percent of the mothers showed moderate or high inhibition, a strikingly high burden of biological exposure in a general population of pregnant women rather than a group of occupationally selected workers.

Alongside the blood measurements, the team administered a structured pesticide-use inventory, classifying the products farmers reported using according to the international IRAC, FRAC and HRAC classification systems for insecticides, fungicides and herbicides. The picture that emerged was one of heavy reliance on organophosphates, particularly chlorpyrifos and profenofos, alongside pyrethroids and neonicotinoids. Notably, 24.3 percent of the reported use involved pesticide mixtures, including combinations of neonicotinoids with organophosphates — a pattern of co-formulation and co-application that toxicologists increasingly worry about, since different chemical classes can interact in ways that single-compound risk assessments do not capture.

When the infants reached approximately six months of age, the researchers assessed their development using the Malawi Developmental Assessment Tool, an instrument designed and validated for African settings that evaluates four domains: gross motor function, fine motor function, language and hearing, and social behavior. The overall picture was reassuring at the population level. Most infants — 88.4 percent — showed normal composite development, and across the individual domains, between 94.7 and 97.3 percent scored within normal ranges. Yet beneath that generally healthy surface, the statistical analysis revealed a consistent signal tied to prenatal exposure.

Using parsimonious multivariable Firth penalized logistic regression — a technique chosen because it produces more stable estimates when outcomes are imbalanced and sample sizes are modest — the researchers found that high maternal acetylcholinesterase inhibition, indicating high pesticide exposure, was associated with roughly triple the odds of mild or delayed composite neurodevelopment in the infants, with an adjusted odds ratio of 2.94 and a 95 percent confidence interval of 1.02 to 8.33, reaching statistical significance at p equal to 0.045. The confidence interval was wide, reflecting the modest number of delayed cases, but the association aligned with a substantial body of evidence from other parts of the world.

Perhaps the most intriguing finding was a significant interaction between pesticide exposure and the sex of the child, with an adjusted odds ratio of 4.30 and a 95 percent confidence interval of 1.05 to 17.56, at p equal to 0.042. This suggests that the relationship between maternal pesticide exposure and infant neurodevelopment may differ for boys and girls, echoing a recurring theme in the environmental health literature, where male fetuses have often appeared more vulnerable to neurotoxic insults, although the direction and magnitude of sex differences vary across studies. The authors themselves are careful to note that this particular estimate was imprecise and requires confirmation in larger, adequately powered, sex-stratified analyses before firm conclusions can be drawn.

The study also identified protective social factors. Mothers who had completed secondary or tertiary education had lower odds of having an infant with mild or delayed composite development, with an adjusted odds ratio of 0.47 and a confidence interval of 0.22 to 1.00, just crossing the threshold of significance at p equal to 0.050. Increasing maternal age was associated with lower odds of language and hearing delay, with an adjusted odds ratio of 0.86 per year of age and a confidence interval of 0.74 to 0.99 at p equal to 0.042. These findings underscore that developmental risk in such communities is shaped by a web of influences — schooling, maternal experience, household environment — that interact with chemical exposures rather than operating in isolation.

The broader context gives the findings weight. Agricultural intensification in Tanzania’s Southern Highlands has driven a marked increase in reliance on organophosphate pesticides, and evidence from cohorts such as the CHAMACOS study of farmworker families in California has linked prenatal organophosphate exposure to poorer cognitive, motor and behavioral outcomes in childhood. What has been missing is data from low- and middle-income countries, and especially from sub-Saharan African smallholder communities, where women often work in the fields themselves, handle concentrates without adequate personal protective equipment, and face exposure through spraying, mixing, re-entering treated plots and laundering contaminated clothing. This study provides a rare, early-window measurement in exactly that population, and it does so using an objective biomarker rather than self-reported exposure alone.

The authors emphasize that the cross-sectional design, the single exposure measurement in the first trimester, and the wide confidence intervals all counsel caution, and they call for longitudinal studies incorporating repeated, pesticide-specific exposure measurements, longer neurodevelopmental follow-up and properly powered sex-stratified analyses. Still, the practical implications are immediate. The team recommends strengthening safer pesticide-use practices in horticultural communities, providing antenatal counseling on occupational exposure, and building developmental surveillance into routine reproductive and child health services so that infants at elevated risk are identified early. The work was funded by Tanzania’s Ministry of Education, Science and Technology through the Higher Education for Economic Transformation Project, and approved by the Catholic University of Health and Allied Sciences and Bugando Medical Centre Research Ethics and Review Committee. For the farming families of Iringa and Njombe, the message is that the first weeks of pregnancy may be a critical window in which pesticide exposure leaves measurable traces in an infant’s developing nervous system — and that protecting mothers in those early months is an investment in the next generation’s minds.

Subject of Research: Prenatal organophosphate pesticide exposure and infant neurodevelopment in Tanzanian smallholder farming communities

Article Title: First-trimester maternal erythrocyte acetylcholinesterase activity and neurodevelopmental outcomes at 6 months among children of smallholder horticultural growers in the Southern Highlands of Tanzania

Article References: Chilipweli, P. M., Nyanza, E. C., Ngowi, A. V., & Manji, K. (2026). First-trimester maternal erythrocyte acetylcholinesterase activity and neurodevelopmental outcomes at 6 months among children of smallholder horticultural growers in the Southern Highlands of Tanzania. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07698-2

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07698-2

Keywords: acetylcholinesterase, organophosphate pesticides, chlorpyrifos, neurodevelopment, Malawi Developmental Assessment Tool, prenatal exposure, smallholder horticulture, Tanzania, infant health, occupational exposure, child sex differences, public health

Against this backdrop, a research team from the ICMR National Institute of Traditional Medicine in Belagavi, working with colleagues at KLE College of Pharmacy, has turned to a plant with deep roots in traditional medicine. Plumbago zeylanica, known in Ayurvedic practice as chitraka, has long been used across the Indian subcontinent for wound healing and inflammatory conditions, and folk accounts have credited it with value against snakebite. The new study, published in the journal 3 Biotech, set out to test whether those traditional claims could survive rigorous modern scrutiny, using a hydromethanolic extract of the plant’s aerial parts against cobra venom in a combined program of laboratory assays, animal experiments and computational modeling.

The in vitro results were striking in their breadth. The extract, abbreviated PZE by the researchers, inhibited phospholipase A2 activity in a dose-dependent fashion, with inhibition ranging from roughly 13 percent at lower concentrations to more than 53 percent at the highest dose tested. Because phospholipase A2 is a principal driver of venom-induced hemolysis, the team also examined its effect on red blood cell destruction and found that the extract reduced PLA2-mediated hemolysis by 46.2 percent. These are not trivial numbers for a crude plant extract, and they suggest that compounds within the aerial parts of the plant can interfere directly with one of the most destructive enzymatic families in elapid venom.

The enzyme-inhibitory profile extended well beyond phospholipase A2. PZE suppressed venom acetylcholinesterase activity by 58.12 percent, an effect with direct relevance to the neurotoxic component of cobra envenomation, since acetylcholinesterase breaks down the neurotransmitter that carries signals from nerve to muscle. Protease activity, which contributes to tissue degradation and hemorrhage, was inhibited by 81.94 percent, the strongest effect recorded in the enzymatic panel. A fluorometric assay also indicated apparent inhibition of collagenase, an enzyme that attacks the collagen scaffolding of connective tissue. Perhaps most tellingly, the extract preserved the alpha chain of fibrinogen, the blood protein that venoms frequently fragment to disrupt clotting, indicating protection of a key substrate at the heart of venom-induced coagulopathy.

Translating these findings into living systems, the researchers challenged mice with twice the lethal dose of cobra venom and treated them orally with the extract at 100 and 200 milligrams per kilogram of body weight. Untreated animals succumbed rapidly, but the treated groups survived significantly longer, with mean survival times of 16 hours 23 minutes and 19 hours 42 minutes at the low and high doses respectively. For comparison, the commercial antisnake venom serum, administered as the current standard of care, provided complete protection for the full 24-hour observation period. The plant extract did not outperform antivenom, and the authors are explicit on this point, but the demonstration that an orally delivered plant preparation can meaningfully extend survival against a supralethal venom challenge is a meaningful proof of concept for an adjunctive therapy that could be administered early, even before a patient reaches a clinic.

The in vivo work also probed the inflammatory and tissue-level consequences of envenomation. At a sublethal challenge of half the lethal dose, venom did not produce significant alterations in the measured serum biomarkers and biochemical parameters, but treatment with the extract reduced venom-associated elevations in interleukin-6 and tumor necrosis factor-alpha, two central cytokines of the inflammatory response, as well as the brain and cardiac isoforms of creatine kinase, enzymes whose release signals damage to neural and muscle tissue. Histopathological examination told a consistent story: venom produced dilatation of the central vein, vascular congestion and mild lymphocytic infiltration in the liver, along with vascular congestion and tubular hemorrhage in the kidney, and the extract markedly ameliorated all of these changes. The pattern suggests that PZE acts not only on venom enzymes themselves but also on the downstream inflammatory storm that venom triggers in host tissues.

To understand which molecular targets might underlie these effects, the team employed network pharmacology, a computational approach that maps the interactions between the phytochemicals in the extract and the host proteins involved in disease pathways. The analysis identified multiple host targets connected through inflammatory, immune and neuronal signaling networks, providing a systems-level rationale for why a crude extract containing many different compounds could produce such broad protective effects. This multitarget character is precisely what conventional single-molecule drug development struggles to achieve against a venom that is itself a complex cocktail of toxins, and it mirrors the logic by which polyvalent antivenoms work, albeit through entirely different molecular means.

The computational arm of the study went further, using molecular docking and molecular dynamics simulations to examine how individual constituents of the extract interact with venom enzymes at atomic resolution. Two flavonoid compounds, 6-C-fucosylluteolin and 6-C-galactosylluteolin, emerged as the most interesting candidates. Docking placed both molecules within the catalytic sites of acetylcholinesterase and phospholipase A2, and the molecular dynamics simulations demonstrated that these interactions remained stable over the simulated timescales, indicating that the binding is not a fleeting artifact but a physically plausible mode of enzyme inhibition. While docking and simulation cannot by themselves prove activity in a patient, they provide a mechanistic scaffold that connects the observed biochemical inhibition to specific compounds that can now be isolated, tested and potentially optimized.

The authors position PZE not as a replacement for antivenom but as a candidate adjunctive phytotherapeutic intervention for the early management of snakebite envenomation, to be used alongside conventional therapy. The logic is compelling. Antivenom must be administered in a clinical setting, is expensive, carries a risk of adverse reactions including anaphylaxis, and is often unavailable in the rural areas where bites occur. A plant-derived oral preparation that could blunt local tissue destruction and dampen inflammation during the critical window before antivenom is given would address a genuine gap in the treatment pathway, particularly in South Asia, where the socioeconomic burden of snakebite is enormous and where traditional plant remedies already occupy a trusted place in first-response practice.

Considerable work remains before any such therapy could reach patients. The active constituents need to be fully characterized and standardized, dose-response relationships and safety margins must be established in accordance with internationally recognized toxicology guidelines, and the protective effects demonstrated here in mice must be validated against the biogeographical variation that is known to exist in cobra venom across India, a variation that already challenges the efficacy of existing antivenoms. Clinical efficacy, drug interactions and the pharmacokinetics of the relevant flavonoids in envenomated patients all remain open questions. Nevertheless, the study represents a rigorous, multi-level validation of a traditional remedy, combining classical enzyme assays, survival studies, histopathology, cytokine profiling, network pharmacology and molecular simulation into a single coherent case. In doing so, it transforms an ethnobotanical claim from folklore into a testable hypothesis, and it adds Plumbago zeylanica to the short but growing list of medicinal plants whose anti-venom potential has survived contact with modern experimental science.

Subject of Research: Evaluation of Plumbago zeylanica aerial part extract as a multitarget adjunctive therapy against Naja naja snake venom

Article Title: Anti-envenomation potential of Plumbago zeylanica aerial part extract against Naja naja: experimental validation and mechanistic insights

Article References: Anti-envenomation potential of Plumbago zeylanica aerial part extract against Naja naja: experimental validation and mechanistic insights. (n.d.). https://doi.org/10.1007/s13205-026-05067-5

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05067-5

Keywords: snakebite, Naja naja, Plumbago zeylanica, antivenom, phospholipase A2, acetylcholinesterase, network pharmacology, molecular docking, phytotherapy, envenomation, flavonoids, traditional medicine

The research team, led by The-Huan Tran, Thai-Son Tran and Thanh-Dao Tran of the University of Medicine and Pharmacy at Ho Chi Minh City and Hue University in Vietnam, constructed an integrative in silico workflow to mine a molecular library derived from known inhibitors of both enzymes, including the cholinesterase drug rivastigmine and the monoacylglycerol lipase inhibitors JZL-184 and ABX-1431. Acetylcholinesterase breaks down the neurotransmitter acetylcholine, and its inhibition has long underpinned symptomatic Alzheimer’s therapy. Monoacylglycerol lipase, by contrast, degrades 2-arachidonoylglycerol, an endocannabinoid signaling lipid whose preservation has been linked to dampened neuroinflammation and enhanced glial immunity. Hitting both enzymes with a single molecule could, in principle, address cognitive decline and inflammatory damage at the same time.

Starting from 365 candidate compounds, the investigators carried out molecular docking against crystal structures of human acetylcholinesterase and human monoglyceride lipase, using AutoDock Vina to predict binding poses and scores. They then applied interaction-based filtering to retain only those ligands that reproduced the key contacts characteristic of known inhibitors, followed by in silico prediction of absorption, distribution, metabolism and excretion properties and toxicity. This successive narrowing of the chemical space reflects a widely adopted paradigm in early-stage drug discovery, where computational filters are stacked so that only chemically sensible, pharmacokinetically plausible candidates advance to the most expensive and time-consuming analyses.

One compound, designated H34, rose to the top of the ranking. Molecular dynamics simulations run with GROMACS under the CHARMM36 force field examined the structural stability of the H34-enzyme complexes over time, tracking the root-mean-square deviation of the protein backbone, the root-mean-square fluctuations of individual residues, the radius of gyration and the solvent-accessible surface area. Across these metrics, the H34 complexes displayed comparatively favorable stability, suggesting that the ligand does not disrupt the overall fold of either enzyme and remains seated in the binding pocket under physiologically realistic conditions.

To move beyond qualitative stability assessments, the team estimated binding free energies using the MM/GBSA end-state method implemented in the gmx_MMPBSA tool. H34 yielded estimated binding free energies of −30.96 and −37.34 kcal/mol for the two enzyme targets, values that compare favorably within the context of the screened series and support the compound’s predicted affinity for both proteins. These calculations decompose the interaction into electrostatic, van der Waals and solvation contributions, offering a thermodynamic rationale for why the molecule holds on to each active site.

Further dynamical profiling added depth to the picture. ProLIF interaction mapping, which encodes protein-ligand contacts as fingerprints across the simulation trajectory, showed that the interactions anchoring H34 in each active site persisted over time rather than flickering in and out. Free energy landscape analysis, built on dihedral angle principal component analysis, mapped the conformational behavior of the complexes and revealed energetically stable basins, indicating that the ligand-bound enzymes do not wander between widely divergent conformations. Together, these analyses portray a compound whose binding mode is not merely a static docking artifact but a durable, low-energy arrangement.

Drug-likeness and safety filters reinforced the computational case for H34. SwissADME-based pharmacokinetic predictions indicated favorable properties relevant to oral absorption and brain exposure, while ProTox 3.0 predictions pointed to low acute toxicity. Because any candidate intended for Alzheimer’s disease must reach the central nervous system without accumulating liability elsewhere, these early pharmacokinetic and toxicological signals, though still predictive rather than experimental, are a meaningful part of the triage process that decides which molecules justify synthesis and laboratory testing.

The study’s authors are careful to frame H34 as a candidate rather than a drug. All findings derive from computational models, and docking scores, MM/GBSA estimates and simulations can only approximate the thermodynamics and kinetics of real enzyme inhibition. The necessary next steps include chemical synthesis and in vitro enzyme assays to measure actual inhibitory potency against both acetylcholinesterase and monoacylglycerol lipase, followed by cell-based and ultimately animal studies to test whether the dual-target hypothesis translates into cognitive and anti-inflammatory benefit in living systems.

Even so, the work illustrates why integrated computational strategies have become indispensable in multi-target drug discovery. By combining ligand-based library generation, structure-based docking, interaction fingerprinting, molecular dynamics, free energy estimation and ADME and toxicity prediction in a single pipeline, the researchers compressed an enormous search space into one well-characterized hit in silico. If H34 or its analogs survive experimental validation, the compound family could contribute to a new generation of multi-target-directed ligands designed for the complexity of Alzheimer’s disease, where modulating a single pathway has repeatedly fallen short.

Subject of Research: Computational discovery of dual acetylcholinesterase and monoacylglycerol lipase inhibitors for Alzheimer's disease

Article Title: Computational discovery and dynamic profiling of dual acetylcholinesterase and monoacylglycerol lipase inhibitors for Alzheimer’s disease

Article References: Tran, T.-H., Tran, T.-S., & Tran, T.-D. (2026). Computational discovery and dynamic profiling of dual acetylcholinesterase and monoacylglycerol lipase inhibitors for Alzheimer’s disease. Molecular Diversity. https://doi.org/10.1007/s11030-026-11725-w

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11725-w

Keywords: Alzheimer's disease, acetylcholinesterase, monoacylglycerol lipase, dual inhibition, molecular docking, molecular dynamics, MM/GBSA, virtual screening, drug discovery, neuroinflammation, multi-target ligands, ADME prediction

Cognitive impairment is one of the defining features of neurodegenerative disorders such as Alzheimer’s disease, and it arises from a convergence of damaging processes rather than a single failure point. The research team, led by Sami I. Alzarea of Jouf University in Saudi Arabia together with colleagues at several Saudi and Indian institutions, focused on four intertwined culprits: dysfunction of the cholinergic neurotransmitter system, oxidative stress, neuroinflammation, and the loss of neuroplasticity, the brain’s capacity to rewire and adapt. Because acemannan, an acetylated beta-(1→4)-linked polymannan, is already known to possess antioxidant and anti-inflammatory properties, the investigators reasoned that it might counter several of these processes at once.

To test that idea, the researchers used Wistar rats treated with scopolamine, a drug that blocks acetylcholine receptors and reliably produces learning and memory deficits that mirror aspects of Alzheimer’s pathology. Scopolamine models are widely used in preclinical dementia research precisely because the compound rapidly disrupts cholinergic signaling, elevates oxidative damage, and triggers inflammatory responses in the hippocampus and cortex. Animals in the study were assessed with a battery of established behavioral instruments: the Morris Water Maze for spatial learning and memory, the Y-maze for working memory, the Novel Object Recognition test for recognition memory, and the rotarod test for motor coordination.

The results were striking. Rats given scopolamine performed poorly across the behavioral suite, showing impaired navigation, reduced spontaneous alternation, diminished recognition of novel objects, and compromised motor performance. Biochemical analysis of brain tissue confirmed the expected damage: distorted levels of the neurotransmitters acetylcholine, GABA, dopamine, serotonin, and glutamate; disturbed activity of the cholinergic enzymes acetylcholinesterase and choline acetyltransferase; elevated malondialdehyde and nitric oxide, both hallmarks of oxidative injury; and surging levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Histopathology revealed degenerating pyramidal neurons, the workhorse cells of memory circuitry.

Acemannan treatment turned much of this picture around. Treated animals improved their performance in the water maze, Y-maze, and object recognition tasks, and recovered motor function on the rotarod. At the molecular level, the polysaccharide restored neurotransmitter balance, normalized the cholinergic enzymes, and reduced oxidative stress markers while boosting the antioxidant defenses of the brain, including superoxide dismutase, catalase, and reduced glutathione. Inflammatory cytokine levels fell, and the cell-death executor caspase-3 was decreased. Perhaps most strikingly, acemannan increased the expression of neuroplasticity markers, brain-derived neurotrophic factor, CREB, SIRT1, and PGC-1α, a signaling quartet central to learning, memory consolidation, and neuronal resilience.

The histological evidence reinforced the biochemical story. Brains from acemannan-treated rats showed substantial neuroprotection, with pyramidal cells appearing mostly normal under the microscope, a sharp contrast to the degeneration observed in the scopolamine-only group. The researchers also demonstrated an inhibitory effect of acemannan on acetylcholinesterase in vitro, the same enzymatic target exploited by several approved Alzheimer’s drugs, suggesting a plausible mechanism for the restored acetylcholine signaling seen in vivo.

To probe how acemannan might engage its molecular targets directly, the team turned to GlycoTorch Vina, a carbohydrate-specific molecular docking tool. Carbohydrates pose unusual challenges for conventional docking software because of their flexibility and complex hydrogen-bonding patterns, making a glycan-specialized approach particularly appropriate. The docking results showed that acemannan binds favorably to the muscarinic acetylcholine receptor CHRM1, with binding energies ranging from −6.1 to −5.4 kcal/mol, the strongest interaction observed. Weaker but still favorable affinities were predicted for brain-derived neurotrophic factor (−4.8 to −4.4 kcal/mol) and TNF-α (−4.3 to −3.0 kcal/mol), hinting that a single sugar polymer could simultaneously touch cholinergic, neurotrophic, and inflammatory pathways.

What makes the study notable is its breadth. Rather than testing a single endpoint, the authors connected behavior, neurotransmitter chemistry, enzymology, oxidative stress, cytokine biology, apoptosis, neuroplasticity signaling, tissue pathology, and computational structural biology into one coherent picture. The convergence of evidence from so many angles strengthens the case that acemannan’s effect is not an artifact of any one assay but reflects genuine, multi-mechanism neuroprotection in this animal model. The work was funded by the Deanship of Graduate Studies and Scientific Research at Jouf University, and the authors report no conflicts of interest.

Acemannan itself has an interesting history. It is the principal bioactive polysaccharide of Aloe vera gel, and earlier toxicological studies dating back decades evaluated injectable formulations in mice, rats, and dogs with acceptable safety profiles. More recent work has explored its role in wound healing, immune modulation, and even diabetes, where it attenuated inflammatory cytokines and apoptosis in a rat model. The new findings extend this portfolio into neuroscience, a field where naturally sourced bioactive polysaccharides are attracting growing interest as sources of low-toxicity, multi-target protective agents.

Caution is nonetheless warranted before celebrating a brain-boosting aloe remedy. The evidence remains preclinical, derived from a chemically induced model in rats rather than from human patients with Alzheimer’s or other dementias, and questions of dosage, bioavailability, blood-brain barrier penetration, and long-term safety in the context of cognitive disease remain open. Scopolamine-induced impairment, while useful, captures only a slice of the pathology of human neurodegeneration. Still, the study offers a rigorous proof of concept that a sugar molecule from a common succulent can shield the brain through cholinergic, antioxidant, anti-inflammatory, and neuroplastic mechanisms at once. If future studies confirm and extend these results, acemannan could join a promising class of natural polysaccharides under investigation for protecting the aging mind.

Subject of Research: Neuroprotective effects of the Aloe vera polysaccharide acemannan against scopolamine-induced cognitive impairment in rats

Article Title: Acemannan as a potential therapeutic agent for cognitive impairment via modulation of cholinergic, oxidative, and inflammatory pathways: in vivo and in silico evidence

Article References: Alzarea, S. I., Alsahli, T. G., Alzarea, A. I., Almutairi, M., Alquraini, A., Zafar, A., & Sayyed, N. (2026). Acemannan as a potential therapeutic agent for cognitive impairment via modulation of cholinergic, oxidative, and inflammatory pathways: in vivo and in silico evidence. 3 Biotech, 16(10), Article 439. https://doi.org/10.1007/s13205-026-05068-4

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05068-4

Keywords: acemannan, Aloe vera, cognitive impairment, neuroprotection, scopolamine, oxidative stress, neuroinflammation, molecular docking, Alzheimer's disease, BDNF, acetylcholinesterase, Wistar rats

The experimental design was deliberately comprehensive. Eighty-four adult male Wistar rats, each weighing between 100 and 120 grams, were randomly assigned to six groups. One group served as a control and received only deionized water, while the remaining five groups received sodium fluoride dissolved in deionized water at concentrations of 25, 50, 100, 150, and 300 parts per million, equivalent to 25 to 300 milligrams per liter. These doses deliberately exceed the World Health Organization guideline value of 1.5 milligrams per liter for fluoride in drinking water, but they fall within or above concentrations actually reported in groundwater from regions where fluorosis is endemic, making the findings directly relevant to millions of people worldwide who rely on fluoride-contaminated water sources. Seven rats from each group were evaluated at the 30-day mark and seven at 60 days, allowing the researchers to distinguish short-term from longer-term effects.

Behavioral testing using the open field assay revealed striking disturbances in both locomotion and anxiety-like behavior. In the 30-day exposure groups, rats receiving 25 milligrams per liter traveled significantly shorter distances and moved more slowly than controls, while animals at 50, 150, and 300 milligrams per liter showed significant reductions in maximum speed. Perhaps most tellingly, the treated rats exhibited disrupted movement patterns: increased angular velocity and meandering, reduced ability to maintain a straight path, and elevated anticlockwise rotation. Rats at the highest dose of 300 milligrams per liter showed markedly reduced freezing latency, suggesting an anxiety profile fundamentally different from controls. At 60 days, the pattern shifted, with some doses increasing distance traveled while others decreased mobility time, altered freezing behavior, and disrupted path efficiency, indicating that the behavioral consequences of fluoride exposure evolve over time rather than simply worsening in a linear fashion.

Beneath these behavioral changes, the biochemical assays painted a picture of severe oxidative stress in two critical brain regions, the hippocampus and the striatum. Malondialdehyde, a marker of lipid peroxidation and cellular membrane damage, rose in a dose-dependent fashion after 30 days of exposure. Hydrogen peroxide levels climbed while the brain’s antioxidant arsenal collapsed: reduced glutathione, superoxide dismutase, and glutathione peroxidase all declined significantly across treated groups. The brain is especially vulnerable to this kind of oxidative assault because it consumes enormous quantities of oxygen and is packed with polyunsaturated fatty acids that are prime targets for free radical attack. The researchers note that fluoride appears to suppress antioxidant defenses both directly, through competitive inhibition of protective enzymes, and indirectly, by generating a flood of reactive oxygen species that overwhelms them.

One of the most consistent findings across every dose and every time point was a significant reduction in acetylcholinesterase activity in both the hippocampus and the striatum. Acetylcholinesterase is the enzyme responsible for breaking down acetylcholine, a neurotransmitter central to learning, memory, attention, and motor control. Its inhibition means acetylcholine lingers longer at synapses, disrupting normal cholinergic transmission. This mechanism is pharmacologically significant because acetylcholinesterase inhibition is also the mode of action of certain nerve agents and pesticides, and reduced cholinergic transmission is implicated in cognitive decline. The authors suggest that the disrupted motor function and altered emotional states observed in the open field tests may be directly linked to this cholinergic impairment, providing a mechanistic bridge between molecular chemistry and observable behavior.

The immunohistochemical analysis added structural evidence to the biochemical story. In the striatum, the researchers documented elevated immunoreactivity for glial fibrillary acidic protein, or GFAP, a hallmark marker of astrocyte activation. Astrocytes normally support neurons by secreting neurotrophic factors, but when they proliferate excessively in response to injury, a process called astrogliosis, they can obstruct neurite outgrowth and impede tissue regeneration. After 60 days of exposure, the increase in astrocyte population was particularly pronounced. Gliosis is the brain’s intrinsic response to damage, and its presence here confirms that sodium fluoride exposure registers in the brain as genuine injury rather than a transient, reversible perturbation.

Equally concerning was the fate of the myelin sheath, the fatty insulation that wraps nerve fibers and enables rapid, efficient signal transmission. Rats exposed to sodium fluoride for both 30 and 60 days showed significantly reduced immunoreactivity for myelin basic protein in the corpus callosum, the massive fiber bundle connecting the brain’s two hemispheres. Demyelination is a serious form of neurological damage, characteristic of diseases such as multiple sclerosis, and its occurrence following chemical toxicity is well documented. The loss of myelin basic protein indicates breakdown of the intact myelin sheath, which would slow or scramble communication between brain regions and could plausibly underlie the motor coordination deficits and abnormal movement patterns recorded in the behavioral tests. Previous research has shown that fluoride can induce degenerative changes across the brain and spinal cord, including axonal degradation, mitochondrial impairment, and synaptic ultrastructural changes, and this study adds region-specific myelin loss to that inventory of harm.

Integrating these findings, the authors propose a coherent mechanistic chain: sodium fluoride exposure generates reactive oxygen species, depletes antioxidant defenses, and drives lipid peroxidation; this oxidative environment damages cholinergic neurons and triggers astrocytic proliferation; the resulting neuroinflammation and myelin degradation cumulatively degrade motor function, coordination, and anxiety regulation. The study’s strength lies in this multi-level convergence, linking behavioral observation with biochemical assay and structural histology in the same animals, something many earlier single-endpoint studies could not do. The connection to human health is not lost on the researchers, who note that epidemiological studies in regions with fluoride levels far exceeding WHO standards have reported significantly lower IQ scores in children, and that both juvenile and adult subjects exposed to elevated fluoride show diminished learning capacity and memory deficits.

The authors are careful to acknowledge the limitations of their work. All experiments were conducted in male rats, and since sex-specific differences in toxin susceptibility are widely reported, the findings may not fully generalize to females. Future studies incorporating female animals will be needed to determine whether these effects are sex dependent. The doses used, while environmentally relevant to fluorosis-endemic regions, sit well above typical fluoridated municipal water levels, so the results should not be read as an indictment of water fluoridation at recommended concentrations. Nevertheless, for the substantial populations in countries including Nigeria, India, Kenya, and China who drink groundwater with fluoride concentrations matching or exceeding those tested here, the implications are sobering. The study demonstrates that fluoride at these levels compromises brain health through oxidative stress, astrocytosis, and disrupted myelination, ultimately producing measurable neurobehavioral impairment, and it provides a detailed mechanistic framework that future protective interventions, whether antioxidant, cholinergic, or anti-inflammatory, can now be tested against.

Subject of Research: Neurotoxic effects of 30- and 60-day sodium fluoride exposure on behavior, brain chemistry, and myelin integrity in adult Wistar rats

Article Title: 30- and 60-days exposure of sodium fluoride induces neurobehavioral deficits and alters neurochemical parameters in adult Wistar rats

Article References: 30- and 60-days exposure of sodium fluoride induces neurobehavioral deficits and alters neurochemical parameters in adult Wistar rats. (n.d.). https://doi.org/10.1007/s44339-026-00051-3

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00051-3

Keywords: sodium fluoride, neurotoxicity, oxidative stress, Wistar rats, acetylcholinesterase, myelin basic protein, GFAP, hippocampus, striatum, corpus callosum, neurobehavioral deficits, fluoridation